Last reviewed · How we verify
NCT06673914
EFFECTS OF OLEUROPEIN ON BLOOD PARAMETERS AND INFLAMMATORY MARKERS IN ADULTS WITH METABOLIC SYNDROME
NA trial testing Control Group: Diet Group in Metabolic Syndrome in 34 participants. Participants enrolled and being followed up; not accepting new ones.
30 December 2024
Quick facts
| Lead sponsor | Atlas University |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 34 |
| Start date | 1 November 2024 |
| Primary completion | 30 December 2024 |
| Estimated completion | 15 January 2025 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Control Group: Diet Group
- Oleuropein and Diet Group
Conditions studied
- Metabolic Syndrome — all drugs for Metabolic Syndrome →
- Insulin Resistance — all drugs for Insulin Resistance →
- Obesity, Abdominal — all drugs for Obesity, Abdominal →
- Obesity — all drugs for Obesity →
Sponsor
Atlas University
Who can join
Adults 18 to 49, any sex, with Metabolic Syndrome or Insulin Resistance. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to determine the effect of 6 weeks supplementation of oleuropein on individuals diagnosed with metabolic syndrome. The baseline and end biochemical parameters and anthropometric measurements will be compared with control subjects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06673914
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metabolic Syndrome
Currently open trials in the same condition.
- NCT07501858 — Assessing the Association Between H. Pylori Persistence and the Severity of Insulin Resistance in Patients With Metaboli · recruiting
- NCT06857929 — "Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition" · NA · recruiting
- NCT07237750 — iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss · NA · recruiting
- NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
- NCT07383220 — Effect of Electrical Stimulation and Exercise on Blood Flow in Patients With Resistant High Blood Pressure · NA · recruiting
Other Atlas University trials
Trials by the same sponsor.
- NCT07500129 — Tissue- and Serum-Derived Exosomal microRNAs as Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer · not yet recruiting
- NCT07509723 — Moulage Technique in Child Abuse Recognition · NA · not yet recruiting
- NCT07590245 — Comparative Effects of Sensorimotor Interventions on Hand Performance With Stroke · NA · completed
- NCT07348731 — Non-Pharmacological Methods in Heel Lance · NA · not yet recruiting
- NCT07435597 — Comparing the Effects of Art Therapy and Mandala Application on State Anxiety Levels in Chemotherapy Patients · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06673914 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Atlas University
- Last refreshed: 5 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06673914.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing